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A B S T R A C T
Purpose: An elevated level of S-100B in serum is generally considered to be a biochemical marker of
nervous tissue damage. According to our knowledge, no studies have evaluated the serum S-100B
protein concentration in children with temporal lobe epilepsy. The objective of this study was to
measure the serum levels of S-100B protein in pediatric cases with temporal epilepsy.
Methods: This case-controlled cross-sectional study was performed at the Department of Pediatric
Neurology, Harran University School of Medicine, Sanliurfa, in Turkey. Serum S-100B protein levels were
studied in 19 (12 females, 7 males) children with temporal lobe epilepsy and in 25 (15 females, 10 males)
healthy control subjects. Serum samples were collected within 30 min after a complex partial seizure,
and serum S-100B protein levels were measured with an electrochemiluminescence immunoassay for
the quantiﬁcation of protein (ECLIA kit, Roche1 Diagnostics, Germany).
Results: The mean serum concentration of S-100B protein was 0.12  0.02 mg/L in the temporal lobe
epilepsy group and 0.07  0.01 mg/L in the control group. The patients showed signiﬁcantly elevated S-100B
protein levels compared with healthy controls (P < 0.001).
Conclusion: Our data suggest that increased S-100B protein levels in the serum might reﬂect neuronal
damage in the brains of children with temporal lobe epilepsy. These results do conﬁrm the previous
ﬁndings of elevated S-100B protein levels in adult patients with temporal lobe epilepsy.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Partial epilepsy is deﬁned as seizures that occur as a result of
neuronal discharge in a certain region of the brain, the clinical and
electroencephalography (EEG) ﬁndings of which are related to this
anatomic localization. To date, the pathogenesis of partial epilepsy
has not been fully explained. Recently, many studies have shown
the existence of astrocytosis, particularly in mesial temporal lobe
epilepsy (MTLE).1,2 Astrocytosis has a primary importance in the
etiology of temporal lobe epilepsy. Reactive astrocytosis causes
deﬁcits in neuronal inhibition by causing local synaptic dysfunc-
tion. Thus, an imbalance in the excitatory and inhibitory synapses
may cause epileptiform discharges in these patients.3* Corresponding author. Tel.: +90 505 284 15 68; fax: +90 414 315 11 81.
E-mail address: m.calik80@hotmail.com (M. Calik).
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http://dx.doi.org/10.1016/j.seizure.2012.10.012A number of proteins have been proposed as peripheral
biochemical markers of neuronal damage and glial activation,
including S-100B and neuron-speciﬁc enolase (NSE). S-100B is a
calcium-binding protein found primarily in astroglial and schwann
cells.4,5 Some reports have evaluated serum S-100B protein levels
in adults with epilepsy, including temporal lobe epilepsy (TLE) and
symptomatic and idiopathic partial epilepsies, but the results are
inconclusive.8,9 In this study, to investigate possible neuronal and/
or glial damage at the cellular level in TLE, we measured the levels
of S-100B protein, which is a biochemical marker of neuronal
damage, in patients with TLE.
2. Methods and materials
This case-controlled cross-sectional study was performed at the
Department of Pediatric Neurology, Harran University School
of Medicine, Sanliurfa, Turkey. The study groups consisted of
19 patients (12 females, 7 males) with TLE and a control group ofvier Ltd. All rights reserved.
Table 1
The demographic characteristics and serum S-100B levels of the patients with
temporal lobe epilepsy and the healthy controls.
Parameters Patients
(n = 19)
Controls
(n = 25)
P-value
Age in yearsa 11.0  6.0 8.50  5.0 P = 0.189
Gender, n (%)
Male 7 (36.8) 9 (36.0)
Female 12 (63.1) 16 (64.0)
Number of AEDa 2.0  1.0 –
Duration (years)a 2.7  1.8 –
Epileptic seizure
frequency (per month)a
7.5  5.2 –
Interictal EEG, n (%)
Unilateral temporal 14 (73.6) –
Bilateral temporal 5 (26.4) –
Epilepsy type, n (%) –
Simple partial – –
Complex partial 19 (100) –
Brain MRI ﬁnding, n (%)
No abnormality 15 (78.9) –
Mesial sclerosis 3 (15.7) –
S-100B level (mg/L)a 0.12  0.02 0.07  0.01 P < 0.001
a These table values are expressed in the form of means  SD.
Fig. 1. The graph demonstrating receiver operating curve (ROC) analysis of S-100B
levels in temporal lobe epilepsy patients with an area under the curve of 0.980.
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in the patient group had been diagnosed with TLE on the basis of
their clinical seizure semiology, video-EEG monitoring, and high-
resolution magnetic resonance imaging (MRI) results. Video-EEG
monitoring revealed ictal discharges in 10 cases. The ictal EEG
results indicated repetitive spikes and spike-and-wave discharges
in the left and/or right temporal lobes of these patients. Ictal
recordings could not be obtained in the remaining 9 patients.
Patients with simple partial epilepsy and patients who displayed
extratemporal epileptiform activity in EEG analyses were excluded
from the study. Patients with non-epileptic disorders, such as
electrolyte disturbances, metabolic disorders, acute brain disease
or trauma, and non-epileptic paroxysmal events mimicking
epilepsy, were excluded from the study.
Research ethics approval was obtained from the Ethics
Committee of the Medical School of Harran University. Written
informed consent was obtained from all children/legal guardians.
Serum samples were taken within 30 min after a seizure for S-100B
measurement.7 Venous blood was extracted into serum tubes and
centrifuged for 10 min at 5000 rpm. Samples were then stored at
20 8C until analysis. Hemolyzed samples were not evaluated for
S-100B. Serum S-100B protein levels were measured with an
electrochemiluminescence immunoassay for the quantiﬁcation of
protein (ECLIA kit, Roche1Diagnostics, Germany). The assays were
performed according to the manufacturer’s instructions.
The data were analyzed using SPSS1 for Windows version 11.5
(Chicago, IL, USA). The values for each group are expressed as the
mean  SD. The Kolmogorov–Smirnov test was used to determine
whether the data were distributed normally. Non-parametric tests
were used because the distribution of the groups was not homoge-
neous. The differences between groups were analyzed using the
Mann–Whitney U-test. The results are expressed as the mean  S.D.
P < 0.05 was considered as statistically signiﬁcant.
3. Results
The age of the subjects ranged from 3 to 16 years (11.0  6.0
years) in the study group and 4 to 16 years (8.50  6.0 years) in the
control group. No statistically signiﬁcant differences were found
between the groups in terms of age or gender distribution
(P = 0.189).
All of the patients exhibited typical clinical features of complex
partial seizures. In total, seven patients had a one year history of
TLE. A three year history of TLE was present in ﬁve cases, and a ﬁve
year history of TLE was present in six cases. One patient had a seven
year history of TLE. Only four patients reported experiencing aura;
this phenomenon manifested in the form of epigastric discomfort
in three cases and as an abnormal odor in one instance. The
patients experienced an average monthly epileptic seizure
frequency of 7.5  5.2 (range: 1–20). The demographic details of
the patient and control groups are given in Table 1. The mean serum
concentration of S-100B protein was 0.12  0.02 mg/L in the temporal
lobe epilepsy group and 0.07  0.01 mg/L in the control group. We
found that the serum levels of S-100B protein were signiﬁcantly
elevated in children with temporal lobe epilepsy compared to
controls (P < 0.001) (Table 1). Interictal EEG demonstrated unilateral
temporal epileptiform activity in 12 cases and bilateral temporal
epileptiform activity in 7 cases. Two of the patients were taking
sodium valproate, four were taking carbamazepine, seven were
taking sodium valproate + carbamazepine, and six were taking
sodium valproate + levetiracetam. Brain MRI was carried out for all
temporal lobe epilepsy patients. Brain MRI ﬁndings compatible with
mesial temporal sclerosis were observed in three patients, and
ﬁndings compatible with millimetric non-speciﬁc gliosis were
observed for one patient. Two patients with mesial temporal sclerosis
had a history of febrile convulsion.The receiver operating curve (ROC) analysis of S-100B levels in
TLE patients determined that the area under the ROC curve was
0.980. This analysis revealed that S-100B levels  0.095 in epileptic
patients indicated the presence of TLE with a sensitivity of 94.7%
and a speciﬁcity of 96% (area under the curve of 0.980; 95%
conﬁdence interval of 0.00–1.00) (Fig. 1).
4. Discussion
S-100B is a structural protein of the central nervous system. It is
primarily an astrocytic protein and is widely used as a parameter of
glial activation.5 Animal models of epilepsy and postsurgery brain
specimens from epileptic patients have also demonstrated
elevated S-100B protein levels in brain tissue.10,11 In previous
studies, elevated S-100B protein levels were associated with
various neurological diseases, including traumatic brain injury,
Fig. 2. The boxplot graphic of serum S-100B level in the patients with temporal lobe
epilepsy and in the controls. The differences between the two groups are signiﬁcant
(P < 0.001).
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processes, central nervous system (CNS) infections and many other
brain disorders.6,12,13 However, only a limited number of studies
have examined serum S-100B protein levels in adult patients with
partial epilepsy. Portela et al.9 reported normal serum S-100B
protein levels in patients with focal epilepsy, while Lu et al.8
reported elevated plasma S-100B protein levels in patients with
MTLE when compared with controls. Steinhoff et al.14 reported
high cerebrospinal ﬂuid (CSF) S-100B levels in patients with TLE
compared to controls. In the study by Lu et al.,8 the concentration
of S-100B protein was shown to correlate with the severity of
epilepsy, and patients with hippocampal sclerosis had higher
plasma S-100B levels than those with MTLE without hippocampal
sclerosis.
In our study, we found a signiﬁcant elevation of serum S-100B
protein levels in children with TLE. To our knowledge, this study is
the ﬁrst to report that serum S-100B protein levels are elevated
after TLE in children. In our series, the serum S-100B levels in
children with TLE were much higher than those of the control
group. S-100B protein acts locally in the brain, however, and its
short serum half-life (only approximately 25–113 min) poses
challenges for its measurement.15 The presence of this protein in
blood serum points to the functional and/or morphological
disruption of the blood–brain barrier. High concentrations of
extracellular S-100B proteins may result from the activation of cell
metabolism, cell death and disease.16 An increased serum
concentration of S-100B may be indicative of neuronal damage
in an epileptic brain.
Leutmezer et al.17 studied the serum S-100 levels in 10
patients with TLE at baseline and at 30 min, 3 h, 6 h, 12 h, and 24 h
after an epileptic seizure and found no signiﬁcant differences in
the serum S-100 levels at these various time points. Conversely,
Palmio et al.18 found a signiﬁcant difference in serum S-100 levels
between a TLE patient group and an XTLE (extratemporal lobe
epilepsy) patient group. In this previously published study, the
serum levels of both NSE and S-100 in the TLE group
demonstrated a statistically signiﬁcant increase following an
epileptic seizure, whereas in the XTLE group, no signiﬁcant
changes in NSE and S-100 levels were observed after an epileptic
seizure.
Our clinical samples for S-100B measurement in children
were obtained from serum. These serum samples were acquired
30 min after an epileptic seizure. Our results are consistent with
the previous studies that indicated elevated S-100B protein
levels after TLE-related seizures in adult patients. The observa-
tion of high S-100B levels in children with TLE led us to
hypothesize that brain damage risks are related to the
occurrence of epileptic seizures (Fig. 2). Baseline levels of
S-100B could not be measured in the TLE cases in our study.
However, a signiﬁcant difference has been found between the
patient and control groups with respect to S-100B levels. Our
study marks the ﬁrst investigation in which S-100B levels were
measured in children with TLE, and its ﬁndings have contributed
to the literature regarding this topic.
Through ROC analysis, the current study has also demonstrat-
ed that serum S-100B levels may possess predictive value that
could supplement the results of radiological and non-radiological
tests (e.g. conventional MR imaging, clinical examinations, or EEG
scanning) in TLE patients. A disadvantage of this study is that it
was conducted with only a small number of patients. This
limitation has restricted the deﬁned cut-off value of the ROC
analysis.
In conclusion, the serum S-100B protein level may be a
biochemical marker for neuronal damage in childhood TLE. It is
clear that there is a need for further studies with a larger patient
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